Predictive Oncology Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Predictive Oncology Inc has an operating margin of -12149.1%, meaning the company retains $-12149 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2263.4% the prior year.
Predictive Oncology Inc's revenue declined 82.8% year-over-year, from $493K to $85K. This contraction results in a growth score of 0/100.
Predictive Oncology Inc's current ratio of 0.62 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 5/100, which could limit financial flexibility.
While Predictive Oncology Inc generated -$10.1M in operating cash flow, capex of $10K consumed most of it, leaving -$10.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Predictive Oncology Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Predictive Oncology Inc generates $0.80 in operating cash flow (-$10.1M OCF vs -$12.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Predictive Oncology Inc (POAI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 23 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Predictive Oncology Inc generated $85K in revenue in fiscal year 2024. This represents a decrease of 82.8% from the prior year.
Predictive Oncology Inc's EBITDA was -$10.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.0% from the prior year.
Predictive Oncology Inc generated -$10.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 23.4% from the prior year.
Predictive Oncology Inc reported -$12.7M in net income in fiscal year 2024. This represents an increase of 9.4% from the prior year.
Predictive Oncology Inc held $612K in cash against $0 in long-term debt as of fiscal year 2024.
Predictive Oncology Inc had 444,475 shares outstanding in fiscal year 2024. This represents a decrease of 89.1% from the prior year.
Predictive Oncology Inc's gross margin was 7.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 52.7 percentage points from the prior year.
Predictive Oncology Inc's operating margin was -12149.1% in fiscal year 2024, reflecting core business profitability. This is down 9885.8 percentage points from the prior year.
Predictive Oncology Inc's net profit margin was -14932.3% in fiscal year 2024, showing the share of revenue converted to profit. This is down 12093.5 percentage points from the prior year.
Predictive Oncology Inc invested $21K in research and development in fiscal year 2024. This represents a decrease of 78.9% from the prior year.
Predictive Oncology Inc spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
Predictive Oncology Inc invested $10K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 1.5% from the prior year.
POAI Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4K+34.9% | $3K-97.6% | $110K+1154.7% | $9K-86.9% | $67K+1284.4% | $5K | N/A | $677K |
| Cost of Revenue | $8K-54.1% | $18K-59.6% | $45K+46.4% | $31K+122.4% | $14K-38.2% | $22K | N/A | $98K |
| Gross Profit | -$5K+69.5% | -$16K-123.8% | $65K+396.0% | -$22K-141.2% | $53K+403.8% | -$18K | N/A | $579K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $21K |
| SG&A Expenses | $2.6M+39.3% | $1.9M+2.6% | $1.8M+18.7% | $1.5M-15.6% | $1.8M-21.5% | $2.3M | N/A | $2.3M |
| Operating Income | -$3.3M-23.3% | -$2.7M-16.3% | -$2.3M-9.1% | -$2.1M+14.9% | -$2.5M+31.2% | -$3.6M | N/A | -$2.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$77.7M-3650.5% | -$2.1M+15.2% | -$2.4M-12.6% | -$2.2M+31.8% | -$3.2M+24.6% | -$4.2M | N/A | -$3.2M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
POAI Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.1M-8.7% | $3.4M-41.5% | $5.9M+18.0% | $5.0M-53.0% | $10.6M-0.1% | $10.6M-26.5% | $14.4M-20.6% | $18.2M |
| Current Assets | $1.1M-9.8% | $1.2M-64.9% | $3.5M+56.6% | $2.2M-67.7% | $6.9M+4.9% | $6.6M-34.9% | $10.1M-25.5% | $13.5M |
| Cash & Equivalents | $182K-64.1% | $506K-83.6% | $3.1M+404.7% | $612K-88.5% | $5.3M+2.6% | $5.2M-37.8% | $8.4M-29.9% | $11.9M |
| Inventory | $38K-11.0% | $43K-6.7% | $46K0.0% | $46K-91.9% | $568K+28.6% | $442K+628.2% | $61K-86.2% | $440K |
| Accounts Receivable | $26K+13.3% | $23K-61.6% | $60K+75.2% | $34K-91.2% | $387K-24.0% | $509K+537.2% | $80K-85.3% | $545K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $80.6M+1483.2% | $5.1M-15.4% | $6.0M+16.2% | $5.2M-20.3% | $6.5M-0.8% | $6.5M+6.5% | $6.1M-5.7% | $6.5M |
| Current Liabilities | $79.5M+1967.1% | $3.8M-16.6% | $4.6M+28.3% | $3.6M-22.2% | $4.6M+2.3% | $4.5M+14.3% | $4.0M-5.3% | $4.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$77.4M-4583.0% | -$1.7M-1034.1% | -$146K+28.0% | -$203K-104.9% | $4.1M+1.0% | $4.1M-51.0% | $8.3M-29.0% | $11.7M |
| Retained Earnings | -$262.6M-42.0% | -$184.9M-1.1% | -$182.9M-1.4% | -$180.4M-3.0% | -$175.2M-1.8% | -$172.0M-2.5% | -$167.8M-2.1% | -$164.3M |
POAI Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M+49.8% | -$3.3M-234.2% | -$986K+52.0% | -$2.1M+1.7% | -$2.1M+38.9% | -$3.4M+17.3% | -$4.1M-100.6% | -$2.1M |
| Capital Expenditures | $0 | $0 | $0-100.0% | $6K | $0-100.0% | $3K+111.0% | -$28K+88.6% | -$243K |
| Free Cash Flow | -$1.7M+49.8% | -$3.3M-234.2% | -$986K+52.1% | -$2.1M+1.4% | -$2.1M+38.9% | -$3.4M+17.7% | -$4.2M-80.7% | -$2.3M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$6K-113.7% | -$3K-141.6% | $7K+286.0% | -$4K |
| Financing Cash Flow | N/A | N/A | N/A | N/A | $3.4M+3089.2% | -$112K-0.9% | -$111K-142.8% | $260K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $2K | N/A |
POAI Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -131.0%+448.4pp | -579.4%-638.5pp | 59.1%+309.6pp | -250.5%-329.9pp | 79.4%+441.2pp | -361.8% | N/A | 85.5% |
| Operating Margin | -90654.1%+8520.7pp | -99174.8%-97101.5pp | -2073.3%+21775.6pp | -23848.9%-20184.3pp | -3664.6%+70070.1pp | -73734.8% | N/A | -404.8% |
| Net Margin | -2146264.3%-2069065.9pp | -77198.4%-74983.9pp | -2214.5%+22462.4pp | -24676.9%-19946.8pp | -4730.1%+82113.1pp | -86843.2% | N/A | -467.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -2475.1%-2414.9pp | -60.3%-18.6pp | -41.6%+2.0pp | -43.6%-13.6pp | -30.0%+9.8pp | -39.8% | N/A | -17.4% |
| Current Ratio | 0.01-0.3 | 0.32-0.4 | 0.76+0.1 | 0.62-0.9 | 1.49+0.0 | 1.45-1.1 | 2.55-0.7 | 3.24 |
| Debt-to-Equity | -1.04+2.0 | -3.08+38.2 | -41.25-15.7 | -25.54-27.1 | 1.59-0.0 | 1.62+0.9 | 0.74+0.2 | 0.56 |
| FCF Margin | -45712.1%+77136.2pp | -122848.3%-121954.6pp | -893.7%+22535.4pp | -23429.1%-20324.3pp | -3104.8%+67275.0pp | -70379.9% | N/A | -340.1% |
Note: Shareholder equity is negative (-$203K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.62), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Predictive Oncology Inc's annual revenue?
Predictive Oncology Inc (POAI) reported $85K in total revenue for fiscal year 2024. This represents a -82.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Predictive Oncology Inc's revenue growing?
Predictive Oncology Inc (POAI) revenue declined by 82.8% year-over-year, from $493K to $85K in fiscal year 2024.
Is Predictive Oncology Inc profitable?
No, Predictive Oncology Inc (POAI) reported a net income of -$12.7M in fiscal year 2024, with a net profit margin of -14932.3%.
What is Predictive Oncology Inc's EBITDA?
Predictive Oncology Inc (POAI) had EBITDA of -$10.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Predictive Oncology Inc's gross margin?
Predictive Oncology Inc (POAI) had a gross margin of 7.7% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Predictive Oncology Inc's operating margin?
Predictive Oncology Inc (POAI) had an operating margin of -12149.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Predictive Oncology Inc's net profit margin?
Predictive Oncology Inc (POAI) had a net profit margin of -14932.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Predictive Oncology Inc's free cash flow?
Predictive Oncology Inc (POAI) generated -$10.1M in free cash flow during fiscal year 2024. This represents a 23.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Predictive Oncology Inc's operating cash flow?
Predictive Oncology Inc (POAI) generated -$10.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Predictive Oncology Inc's total assets?
Predictive Oncology Inc (POAI) had $5.0M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Predictive Oncology Inc's capital expenditures?
Predictive Oncology Inc (POAI) invested $10K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Predictive Oncology Inc spend on research and development?
Predictive Oncology Inc (POAI) invested $21K in research and development during fiscal year 2024.
How many shares does Predictive Oncology Inc have outstanding?
Predictive Oncology Inc (POAI) had 444,475 shares outstanding as of fiscal year 2024.
What is Predictive Oncology Inc's current ratio?
Predictive Oncology Inc (POAI) had a current ratio of 0.62 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Predictive Oncology Inc's debt-to-equity ratio?
Predictive Oncology Inc (POAI) had a debt-to-equity ratio of -25.54 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Predictive Oncology Inc's return on assets (ROA)?
Predictive Oncology Inc (POAI) had a return on assets of -254.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Predictive Oncology Inc's cash runway?
Based on fiscal year 2024 data, Predictive Oncology Inc (POAI) had $612K in cash against an annual operating cash burn of $10.1M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Predictive Oncology Inc's debt-to-equity ratio negative or unusual?
Predictive Oncology Inc (POAI) has negative shareholder equity of -$203K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Predictive Oncology Inc's Piotroski F-Score?
Predictive Oncology Inc (POAI) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Predictive Oncology Inc's earnings high quality?
Predictive Oncology Inc (POAI) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Predictive Oncology Inc?
Predictive Oncology Inc (POAI) scores 1 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.